Transgene Stock Surges 7% at Close in an Illiquid Market
At the close of trading on Friday, December 12, 2025, Transgene's stock marked a significant increase of 7.17%, reaching 0.96 euros from 0.89 euros the previous day. This rebound occurred in limited trading volumes, with only 0.09% of the capital being traded during the session. Over the week, the increase now stands at 10.39%, while the performance remains negative over three months (-16.87%) and strongly positive over one year (+33.71%). This volatility reflects a chaotic stock market journey for the Strasbourg-based biotech, recently marked by a dilutive fundraising of 105 million euros at the end of November, leading to an adjusted recommendation from Oddo BHF.
Recent Fundraising and Stock Performance
The biotech raised 105 million euros at the end of November to fund the development of its therapeutic vaccine TG4050, an operation representing more than half of its market capitalization. Following this fundraising, Oddo BHF lowered its price target from 1.60 euros to 1.10 euros while maintaining its 'Outperform' recommendation. This Friday, the stock recovered some of the ground lost when trading resumed after suspension on November 27. Despite this weekly gain of 10.39%, Transgene remains under structural pressure: the price is currently at 0.96 euros, significantly below its 50-day moving average (1.21 euros) and even its 20-day average (1.10 euros). However, the stock is above its 200-day moving average (0.93 euros), the last medium-term technical support. The RSI indicator shows a level of 24, indicating a significant oversold zone that could favor a short-term rebound. Nonetheless, liquidity remains very low with only 0.09% of capital traded, which accentuates the intraday volatility.
Impact of Capital Increase and Fundraising
These two operations of fundraising and capital increase reserved for TSGH resulted in the issuance of 141.4 million new shares, which is 106.5% of the current capital, at a price of 1.02 euros per share representing a discount of 25% compared to the price on November 25. The operation is highly dilutive and the increased control of TSGH reduces the float and liquidity, partly explaining the persistent weakness of volumes. However, Oddo BHF highlights a financial horizon extended from the end of 2026 to the beginning of 2028, which secures the company's financing during the crucial phases of the myvac program. About 70% of the amount raised will be dedicated to accelerating the myvac individualized therapeutic vaccine program, including the phase 1-2 trial in head and neck cancer and a new phase 1 study in a new indication as well as production optimization. This financial security until 2028 distances the specter of an immediate need for refinancing, but the market currently penalizes the massive dilution of capital.
Technical Analysis and Market Behavior
Technically, the situation remains fragile. The MACD shows a bearish setup with a signal line at -0.09 and a negative histogram (-0.02), confirming the lack of a structural bullish momentum. The one-month volatility reaches 27.18%, indicating a particularly nervous stock in a context of low liquidity. The Bollinger Bands frame the price between a support at 0.72 euros and a resistance at 1.48 euros, with the stock currently trading at the lower end of this range. The immediate support threshold is at 0.87 euros, a level already tested recently. The Chaikin Money Flow (CMF) displays -0.38, indicating a persistent outflow of capital and a lack of buying conviction. The negative beta of -0.09 confirms a decoupling from the general market. While the RSI in the oversold zone may generate a tactical rebound, the analysis of flows and moving averages suggests that the stock remains under pressure, especially since the technical resistance at 1.48 euros (upper Bollinger Band) appears difficult to reach in the short term without a major clinical catalyst.
